S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
Phase II Study of Dexamethasone/Alpha-Interferon in AL Amyloidosis
Sponsor: Cancer and Leukemia Group B
Listed as NCT00002849, this PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by Cancer and Leukemia Group B, it has been updated 8 times since 1996, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2023 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Nov 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer and Leukemia Group B
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States, Boston, United States, Buffalo, United States, Burlington, United States, Chapel Hill, United States, Chicago, United States, Columbia, United States, Columbus, United States, Durham, United States, Iowa City, United States and 18 more location s